Development of a Novel Reference Material for Tumor Mutational Burden Measurement Based on CRISPR/Cas9 Technology

As a biomarker that affects treatment decisions of immune checkpoint inhibitors, the accuracy, reliability, and comparability of tumor mutational burden (TMB) estimation is of paramount importance. To improve the consistency and reliability of these tests, qualified reference materials providing gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Rongxue, Lin, Guigao, Li, Lin, Li, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098197/
https://www.ncbi.nlm.nih.gov/pubmed/35574377
http://dx.doi.org/10.3389/fonc.2022.845636

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098197/
https://www.ncbi.nlm.nih.gov/pubmed/35574377
http://dx.doi.org/10.3389/fonc.2022.845636

Ejemplares similares